Imipramine
CAS No. 50-49-7
Imipramine( —— )
Catalog No. M33650 CAS No. 50-49-7
Imipramine (Dimipressin) is an orally active Fascin1 inhibitor with antidepressant and antitumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 49 | Get Quote |
|
| 10MG | 81 | Get Quote |
|
| 25MG | 158 | Get Quote |
|
| 50MG | 247 | Get Quote |
|
| 100MG | 385 | Get Quote |
|
| 500MG | 871 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameImipramine
-
NoteResearch use only, not for human use.
-
Brief DescriptionImipramine (Dimipressin) is an orally active Fascin1 inhibitor with antidepressant and antitumor activity.
-
DescriptionImipramine is an orally active tertiary amine tricyclic antidepressant. Imipramine is a Fascin1 inhibitor with antitumor activities. Imipramine also inhibits serotonin transporter with an IC50 value of 32 nM. Imipramine stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine shows neuroprotective and immunomodulatory effects.
-
In VitroImipramine (0.5-300 μM, 3 days) inhibits HCT-116 cell viability.Imipramine (20 μM) inhibits cell migration (7 h) and invasion (48 h).Imipramine (50 μM, 0-240 min) inhibites the PI3K/Akt/mTOR signaling pathway in U-87MG glioma cells.Imipramine (60 μM, 24 h) stimulates U-87MG glioma cells autophagy.Imipramine (80 μM, 24 h) induces HL-60 cell apoptosis.Cell Viability Assay Cell Line:DLD-1, HCT-116, and SW-480 Concentration: 0.5-300 μM Incubation Time:3 days Result:Inhibited cell viability and HCT-116 was more sensitive than DLD-1 and SW-480.Cell Migration Assay Cell Line:DLD-1, HCT-116, and SW-480 Concentration:20 μM Incubation Time:7?h Result:Produced a remarkable inhibition of migration in all assayed cell lines.Cell Invasion Assay Cell Line:HCT-116Concentration:20 μMIncubation Time:48?hResult:Inhibited cell invasion through Matrigel. Western Blot Analysis Cell Line:U-87MG Concentration:50 μM Incubation Time:0, 15, 30, 60, 120 and 240 min Result:Markedly inhibited the phosphorylation of both Akt (Ser473) and mTOR (Ser2481) in a time-dependent manner. Also dephosphorylated p70 S6K, a downstream target of mTOR.Cell Autophagy Assay Cell Line:U-87MG Concentration:60 μM Incubation Time:24 h Result:Stimulated the induction of autophagy through the redistribution of LC3 in U-87MG glioma cells.Apoptosis Analysis Cell Line:HL-60 Concentration:80 μM Incubation Time:24 h Result:Induced cell apoptosis.
-
In VivoImipramine (20 mg/kg, i.p. or 15 mg/kg, p.o.; daily for 24 days) attenuates neuroinflammatory signaling and reverses stress-induced social avoidance in mice.Animal Model:Male C57BL/6 mice (6–8 weeks old) subjected to RSD (repeated social defeat) and HCC (home cage control)Dosage:20 mg/kg or 15 mg/kg Administration:Intraperitoneal injection or oral administration, daily for 24 days Result:Reversed RSD-induced social avoidance behavior, significantly increasing the interaction time, significantly decreased stress-induced mRNA levels for IL-6 in brain microglia.
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number50-49-7
-
Formula Weight280.41
-
Molecular FormulaC19H24N2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC=1C=CC2=C(C1)N(C=3C=CC=CC3CC2)CCCN(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Alburquerque-González B, et al. New role of the antidepressant imipramine as a Fascin1 inhibitor in colorectal cancer cells. Exp Mol Med. 2020 Feb;52(2):281-292.?
molnova catalog
related products
-
Nimbolide
Nimbolide suppresses CDK4/CDK6 kinase activity. Nimbolide inhibits the NF-κB, Wnt, PI3K-Akt, MAPK, and JAK-STAT signaling pathways.
-
RIPK3-IN-1
RIPK3-IN-1 is a selective and potent RIPK3 inhibitor (IC50: 9.1 nM) that inhibits the activities of c-Met kinase, RIPK1 and RIPK2.RIPK3-IN-1 has potential tumorigenic activity and can be used to study apoptosis.
-
TD52
TD52 is an orally active inhibitor of cancerous inhibitor of PP2A (CIP2A). TD52 is an Erlotinib derivative and indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter.
Cart
sales@molnova.com